Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding the science and finance embedded in Olema Pharmaceuticals鈥� disclosures can feel like reading a laboratory notebook written in legalese. The company鈥檚 300-page annual report 10-K details dose-escalation cohorts, while each 8-K material event may reveal fresh trial data that can move the share price overnight. Add in rapid-fire Form 4 insider transactions real-time from executives who live the pipeline every day, and even seasoned biotech investors risk missing critical signals.
Stock Titan eliminates that anxiety. Our AI reads every word the moment it hits EDGAR, delivering Olema Pharmaceuticals SEC filings explained simply. Want the cash-runway line in the latest Olema Pharmaceuticals quarterly earnings report 10-Q filing? It is summarised in plain English beside key metrics. Need an alert when a director buys shares? You will get instant notifications for Olema Pharmaceuticals insider trading Form 4 transactions. Each document comes with side-by-side AI-powered summaries, real-time red-line updates, and expert commentary, so you can focus on decisions rather than deciphering footnotes.
Use the platform to:
- Review Olema Pharmaceuticals earnings report filing analysis for R&D spend versus clinical timelines.
- Track Olema Pharmaceuticals executive stock transactions Form 4 to gauge management conviction.
- Compare historical cash burn in the Olema Pharmaceuticals annual report 10-K simplified.
- Examine the Olema Pharmaceuticals proxy statement executive compensation to understand incentive structures.
- Quickly grasp new data releases with Olema Pharmaceuticals 8-K material events explained.
From understanding Olema Pharmaceuticals SEC documents with AI to spotting trend-shifting disclosures the moment they post, Stock Titan equips you to stay ahead in one of biotech鈥檚 most closely watched stories.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company advancing palazestrant (OP-1250) and a KAT6 inhibitor (OP-3136). At June 30, 2025 the company reported total cash, cash equivalents and marketable securities of $361.9 million (cash and cash equivalents of $52.5 million and marketable securities of $309.4 million) and an available balance of $22.0 million under its loan agreement; management states this liquidity is sufficient to fund the current operating plan for at least the next 12 months. Total assets were $382.0 million with stockholders' equity of $345.2 million.
For the quarter ended June 30, 2025, Olema recorded a net loss of $43.8 million (loss per share $0.51); for the six months the net loss was $74.2 million (loss per share $0.87). Research and development expense was $43.9 million for the quarter and $74.5 million for six months, which included a $10.0 million one-time milestone to Aurigene. The company drew $3.0 million under its Credit Facility and continues collaborations with Novartis and Pfizer to supply CDK4/6 inhibitors for clinical trials; it completed a 2024 private placement that generated approximately $237.0 million net proceeds and maintains an at-the-market program with $150.0 million capacity.
Olema Pharmaceuticals reported its financial results for the quarter ended June 30, 2025 and furnished a press release and an investor presentation as exhibits to this Current Report. The filing identifies the press release as Exhibit 99.1, the investor presentation as Exhibit 99.2, and the cover page interactive data file as Exhibit 104. The company states these materials are being furnished and are not deemed "filed" under Section 18 of the Exchange Act.
The 8-K does not include numerical financial metrics within the text; investors seeking revenue, earnings, or other performance figures must review the attached Exhibit 99.1 press release or Exhibit 99.2 presentation or consult the company website where the presentation was made available.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
